DBV Technologies S.A. - American Depositary Shares (DBVT)
Frequently Asked Questions About DBV Technologies S.A. - American Depositary Shares (DBVT)
Has DBV Technologies received any awards or recognitions?
DBV Technologies has received various awards and recognitions within the biopharmaceutical community for its innovative approaches and contributions to allergy treatment research. These accolades reflect the company's commitment to scientific excellence and its impact on the field of allergy and immunology.
How does DBV Technologies engage with the community?
DBV Technologies engages with the community through outreach and educational initiatives aimed at increasing awareness about food allergies and the importance of research in this field. The company collaborates with patient advocacy groups and participates in public health initiatives to foster greater understanding and support for those affected by allergies.
How does DBV Technologies fund its research and development?
DBV Technologies funds its research and development through a combination of public and private financing, including capital raised from its IPO, subsequent equity offerings, and collaborations with other organizations. Securing grants and funding from research institutions also plays a role in supporting its initiatives.
Is DBV Technologies publicly traded?
Yes, DBV Technologies S.A. is publicly traded on the Nasdaq stock exchange under the ticker symbol DBVT. The company went public in 2014 and has since attracted considerable interest from investors due to its innovative approach to treating allergies.
What are the potential risks associated with investing in DBV Technologies?
Investing in DBV Technologies carries potential risks common to the biopharmaceutical sector, including clinical trial failures, regulatory setbacks, market competition, and the need for continued funding. Investors should carefully consider these risks against the company's innovative potential and future growth prospects.
What are the primary areas of focus for DBV Technologies?
DBV Technologies primarily focuses on the treatment of food allergies, particularly peanut and other food-related allergies. Its research and development pipeline includes various programs centered on immunotherapies that aim to desensitize patients to allergens and reduce the risk of severe allergic reactions.
What clinical trials is DBV Technologies currently conducting?
DBV Technologies is currently conducting clinical trials for its lead product candidate, Viaskin Peanut, among others. These trials are designed to evaluate the safety, tolerability, and efficacy of the therapy in various patient populations, including children and adults with peanut allergies.
What corporate partnerships does DBV Technologies have?
DBV Technologies has engaged in partnerships with various research institutions, pharmaceutical companies, and academic organizations to enhance its research capabilities and clinical development efforts. These collaborations are integral to advancing its pipeline and expanding its technological reach.
What does DBV Technologies S.A. do?
DBV Technologies S.A. is a biopharmaceutical company focused on developing and commercializing innovative immunotherapy treatments for food allergies and other allergic diseases. The company primarily utilizes its proprietary Viaskin technology, which is designed to deliver therapeutic proteins through the skin to promote immune tolerance without the need for injection.
What is DBV Technologies' approach to regulatory submissions?
DBV Technologies follows a comprehensive approach to regulatory submissions by thoroughly conducting preclinical and clinical studies to gather robust data supporting the safety and efficacy of its products. The company works closely with regulatory agencies, including the FDA in the U.S. and the EMA in Europe, to ensure compliance and facilitate the approval process.
What is DBV Technologies' commitment to sustainability?
DBV Technologies is committed to sustainability and corporate responsibility by conducting its operations in an environmentally conscious manner. This includes striving for sustainable practices in its research and operational processes, as well as emphasizing ethical practices in clinical trials and partnerships.
What is the company's long-term vision?
DBV Technologies' long-term vision is to become a leader in the field of immunotherapy for food allergies and to expand its portfolio of treatment options for patients suffering from allergic conditions. The company aims to improve patient outcomes and quality of life by developing safe, effective therapies that address unmet medical needs.
What is the potential market for DBV Technologies' products?
The potential market for DBV Technologies' products, particularly in the realm of food allergies, is significant and growing due to the increasing prevalence of allergic conditions globally. Estimates suggest that food allergies affect millions of individuals, creating a robust market opportunity for effective therapeutic solutions like those developed by DBV.
What is the status of DBV Technologies’ lead product candidate?
DBV Technologies' lead product candidate is Viaskin Peanut, which has been developed to provide desensitization to peanut allergies. The company has pursued regulatory approvals for this product, and as of the latest updates, it has embarked on clinical trials to evaluate its safety and efficacy in pediatric and adult populations.
What is Viaskin?
Viaskin is a unique drug delivery technology developed by DBV Technologies that allows for the transdermal delivery of therapeutic proteins. By applying the therapeutic agent to the skin, Viaskin aims to stimulate the immune system in a way that promotes long-lasting tolerance to allergens, particularly aimed at treating food allergies such as peanut allergy.
What recent developments have occurred with DBV Technologies?
Recent developments at DBV Technologies include advancements in clinical trial data for its product candidates, partnerships with research institutions, and ongoing efforts to secure regulatory approvals for Viaskin Peanut and other pipeline products. These developments aim to enhance the company's position in the biopharmaceutical market.
What role does patient feedback play at DBV Technologies?
Patient feedback is a crucial component of DBV Technologies' development process. The company actively seeks input from clinical trial participants and patients to understand their experiences and perceptions regarding treatment, which helps inform clinical practice and the design of future studies.
Where is DBV Technologies headquartered?
DBV Technologies is headquartered in Montrouge, France, with additional operational facilities in the United States. This international presence supports the company in its mission to address the global challenge of food allergies through innovative therapies.
Who are the key executives at DBV Technologies?
DBV Technologies is led by a team of experienced professionals in the biopharmaceutical industry. Key executives typically include the Chief Executive Officer, Chief Financial Officer, and Chief Medical Officer, who collectively bring diverse expertise in research, development, and commercialization of novel therapies.
What is the current price of DBV Technologies S.A. - American Depositary Shares?
The current price of DBV Technologies S.A. - American Depositary Shares is 7.700
When was DBV Technologies S.A. - American Depositary Shares last traded?
The last trade of DBV Technologies S.A. - American Depositary Shares was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of DBV Technologies S.A. - American Depositary Shares?
The market capitalization of DBV Technologies S.A. - American Depositary Shares is 424.24M
How many shares of DBV Technologies S.A. - American Depositary Shares are outstanding?
DBV Technologies S.A. - American Depositary Shares has 55.10M shares outstanding.